Form 4: Lilly Endowment Sells LLY Shares Under 10b5-1 Plan

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 167,526 shares of common stock on November 19, 2025, under a pre-arranged trading plan.

Summary

• Lilly Endowment Inc., identified as a 10% owner of Eli Lilly & Co. (LLY), reported transactions involving the sale of common stock.
• A total of 167,526 shares of common stock were disposed of on November 19, 2025.
• The sales were executed in multiple transactions at weighted average prices ranging from $1,050.208 to $1,055.081 per share.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.
• Following these transactions, Lilly Endowment Inc. beneficially owns 92,644,452 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 5

Explanation: A Form 4 filing primarily reports factual insider transactions and does not inherently convey positive or negative sentiment about the company's operational or financial performance, especially when executed under a pre-arranged 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Eli Lilly & Co.'s future performance or outlook.

Industry Context

This filing is a routine disclosure of an insider transaction and does not provide information related to broader industry trends or competitive landscape for Eli Lilly & Co.

Stakeholder Impact

• Shareholders: The sale by a 10% owner under a 10b5-1 plan is a routine disclosure and is unlikely to have a significant impact on other shareholders, as it represents a pre-planned divestment rather than a reaction to new company-specific news.

Key Dates

Keywords

Eli Lilly & Co, LLY, Lilly Endowment Inc, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Beneficial Ownership